Facilities & Capacity

Flu has no off-season when it comes to manufacturing, says CSL Seqirus

The 2022/23 influenza season could see Seqirus produce 55 million vaccines for the US alone, but fluctuating demand across hemispheres means the firm must manage scalability in a variety of ways. Seqirus has long had a leading role in the seasonal influenza space through its portfolio of products, including both egg-based and cell-based vaccine. And last month, the firm began shipping its portfolio across the US and claimed it is prepared to supply more than 55 million doses, if required. To…

Lilly working ‘around the clock’ to ensure Mounjaro supply

Two US drug substance and two drug product manufacturing plants are in the works to support the rollout of Eli Lilly’s recently approved type 2 diabetes GLP-1 receptor Mounjaro (tirzepatide). In May, the US Food and Drug Administration (FDA) approved Mounjaro, a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor. Mounjaro represents the first new class of type 2 diabetes medication introduced in almost a decade, and a boost for developer Eli Lilly, which has begun rolling out…

Tosoh to increase media capacity by 70% at Japan plant

Tosoh Bioscience aims to meet the increased demand for separation and purification media by investing $120 million to expand its Nanyo Complex in Shunan City, Japan. According to Tosoh, separation and purification media are critical products of its bioscience division, which are required in the purification process of biopharmaceutical production and various other processes. The firm noted that one of the most important applications is the purification of antibody-derived molecules. Meanwhile, demand for RNA-based vaccines and drugs, other modalities, and…

MilliporeSigma AAV platform aimed at reducing development time

MilliporeSigma, the life sciences division of Merck KGaA, has launched VirusExpress 293 Adeno-associated virus (AAV) production platform, which it says reduces process development time by around 40%. According to MilliporeSigma, the launch of this specific AAV production platform makes the firm one of the first contract development manufacturing organizations (CDMOs) to provide a complete viral vector manufacturing offering, including AAV, CDMO, lentiviral, CTO, and process development. Additionally, the firm said that the Virus Express 293, which is an extension of…

Regenxbio: Inhouse facility a driving force in ‘5×25’ gene therapy ambition

A newly opened inhouse facility gives Regenxbio not just capacity but quality and operations continuity, the firm says as it aims to bring five gene therapies to market by 2025. Earlier this year, gene therapy developer Regenxbio launched a strategy called ‘5×25’ aimed at progressing five adeno-associated virus (AAV) vector-based therapeutics from its internal pipeline and licensed programs into pivotal stage or commercial products by 2025. Around the same time, the firm began operations at a 132,000 square-foot facility in…

OriCell plans CAR-T plant after $120m funding boost

OriCell Therapeutics has closed a $120 million Series B financing set to support its cell therapy and bispecific immunotherapy pipeline. The Shanghai, China-based company also plans to build a clinical/commercial manufacturing plant, though the location or further details are yet to be revealed. OriCell has two chimeri antigen receptor (CAR) T candidates that are close to clinical stage, one for advanced liver cancer and the other for multiple myeloma. It is also developing a PD-L/4-1BB bispecific antibody that it partnered…

Plasmid production a plus for Polyplus

Polyplus has added transgene plasmid engineering services for viral vector manufacturing, which it says allows customers to get their gene therapies to market quicker. The French biotech claims that since acquiring DNA design and production services firm e-Zyvec in February, it has focused on providing more advanced levels of solutions to support its client base. By using e-Zyvec’s technology “the plasmids are assembled de novo, from a library of DNA bricks, removing the use of standard plasmid backbones that contain…

Thermo Fisher shells out $76m to expand NY cell culture media site

The $76 million investment will increase the cell culture media manufacturing site in Grand Island, New York, which Thermo says is critical to produce vaccines and biologic therapies. The $76 million funding is part of a long-term $650 million investment the firm announced last March and Thermo Fisher Scientific said it aims to meet global demand for cell culture media by expanding its dry powder media manufacturing plant in Grand Island. “Our expanded Grand Island site represents a significant milestone in…

Core Biogenesis bags $10.5m funding to drive plant-based bioproduction

Core Biogenesis has completed a $10.5 million Series A funding round, which will be used to build a plant-based bioproduction facility. The site will be located in Strasbourg, France and the firm said it will be dedicated to manufacturing growth factors and cytokines for the cell therapy space and cellular agricultural industry and will launch early next year. The firm claims it has developed a technology platform that can express recombinant proteins from the seeds of a Camelina sativa oilseed…

Cytiva opens Vancouver robotic aseptic filling site

The site located in the greater Vancouver area will expand manufacturing capacity of aseptic filling machines by over 200%, says Cytiva. The 126,200 square-foot site is situated next to Fraser River in Burnaby, which is less than twenty minutes from Vancouver International Airport, and one hour away from the US border. Work is still ongoing at the existing production site, which the firm acquired from Vanrx Pharmasystems in February 2021, but the firm said a larger space was needed due…